F-1394. Hypolipidemic, ACAT inhibitor

Drugs of the Future

Volumn 23, Issue 7, 1998, Pages 712-717

  Sorbera, L A ^a   Silvestre, J ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS[[1 CYCLOHEPTYL 3 (4 DIMETHYLAMINOPHENYL)UREIDO]METHYL]BENZENE; 1,4 BIS[[1 CYCLOHEXYL 3 (4 DIMETHYLAMINOPHENYL)UREIDO]METHYL]CYCLOHEXANE; 2 [3 (2,2 DIMETHYLPROPYL) 3 NONYLUREIDO]CYCLOHEXANE 1 YL 3 [N (2,2,5,5 TETRAMETHYL 1,3 DIOXANE 4 CARBONYL)AMINO]PROPIONIC ACID; 2,2 DIMETHYL N (2,4,6 TRIMETHOXYPHENYL)DODECANAMIDE; 3 (2,4 DIFLUOROPHENYL) 1 HEPTYL 1 (4 NEOPENTYLBENZYL)UREA; ACA 147; ACB 796; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CLOFIBRATE; EFLUCIMIBE; ELDACIMIBE; EPICOCHIOQUINONE A; FR 186054; KV 2920; KY 455; LECIMIBIDE; MELINAMIDE; N (2,2,5,5 TETRAMETHYL 1,3 DIOXAN 4 YLCARBONYL) BETA ALANINE 2 [N' (2,2 DIMETHYLPROPYL) N'NONYLUREIDO] 1 CYCLOHEXYL ESTER; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PRAVASTATIN; PROBUCOL; R 755; SKK 58099; SULFAMIC ACID ((2,4,6 TRIS (1 METHYLETHYL) PHENYL)ACETYL) 2,6 BIS(1 METHYLETHYL) PHENYL ESTER; TRIACYLGLYCEROL; TS 962; TYLOXAPOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

EID: 0031694354     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.07.466747     Document Type: Article

References (31)

1. Ikawa, H., Matsumoto, H. (Fujirebio, Inc.). Methods of producing pantothenic acid deriv. and its starting materials for producing the same. EP 612740.
2. Ikawa, H., Matsumoto, H., Kobayashi, N., Kusunoki, J. (Fujirebio, Inc.). Pantothenic acid derivs. EP 421441, JP 91218350, JP 91218366, JP 91218340, US 5120738.
3. Ikawa, H., Matsumoto, H., Kobayashi, N., Kusunoki, J., Yamaura, T. Synthesis of ACAT inhibitors. 115th Annu Meet Pharmaceut Soc Jpn (March 29-31, Osaka) 1993, Abst 29PB 15-02.
4. Aragane, K., Kusunoki, J., Kaneshige, M., Yatabe, Y., Yamaura, T., Ohnishi, H. Pharmaco-biochemical properties of F-1394, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor. Jpn J Pharmacol 1994, 64(Suppl. 1): Abst P-625.
5. Kusunoki, J., Aragane, K., Yamaura, T., Ohnishi, H. Studies on acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory effects and enzyme selectivity of F-1394, a pantothenic acid derivative. Jpn J Pharmacol 1995, 67: 195-203.
6. Kusunoki, J., Aragane, K., Kitamine, T., Higashinakagawa, S., Kase, N., Yamaura, T., Ohnishi, H. Hypocholesterolemic action and prevention of cholesterol absorption via the gut by F-1394, a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, in cholesterol diet-fed rats. Jpn J Pharmacol 1995, 69: 53-60.
7. Aragane, K., Kusunoki, J., Kitamine, T., Yamaura, T., Ohnishi, H. Effects of F-1394, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on ACAT activity in HepG2 cells and on hepatic secretion of lipids in Triton WR-1339-induced hyperlipidemic rats: Possible role of hepatic ACAT in very low density lipoprotein secretion. Jpn J Pharmacol 1998, 76: 309-12.
8. Kusunoki, J., Aragane, K., Kitamine, T., Kozono, H., Sekine, Y. Effect of F-1394, an ACAT inhibitor, on the postprandial hyperlipidemia induced in streptozotocin-diabetic rats. 13th Int Symp Drugs Affect Lipid Metab (May 30-June 3, Florence) 1998, 49.
9. Yamashita, S., Islam, A., Ishigami, M., Nakamura, T., Kusunoki, J., Aragane, K., Kitamine, T., Yamaura, T., Ohnishi, H., Matsuzawa, Y. Effects of a novel ACAT inhibitor F-1394 on the progression and regression of atherosclerotic lesions in the aorta of cholesterol-fed rabbits. 12th Int Symp Drugs Affect Lipid Metab (Nov 7-10, Houston) 1995, 49.
10. Kusuno, J., Aragane, K., Kitamine, T., Yamaura, T., Ohnishi, H. Hypolipidemic action of F-1394, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, in high-fat diet fed beagle dogs. Yakugaku Zasshi 1997, 117: 233-41.
11. Kusunoki, J., Aragane, K., Kitamine, T., Yamaura, T., Ohnishi, H. Effect of F-1394, a potent and selective inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), on esterification of cholesterol and basolateral secretion of cholesteryl ester in Caco-2 cells. Folia Pharmacol Jpn 1997, 110: 357-65.
12. Vaccaro, W., Amore, C., Berger, J., Burner, R., Clader, J., Davis, H., Domalski, M., Fevig, T., Salisbury, B., Sher, R. Inhibitors of acyl CoA:cholesterol acyltransferase. J Med Chem 1996, 39: 1704-19.
13. Adelman, S.J., McKean, M.L., Prozialeck, D.H., Clark, D.E., Fobare, W.F. ACA-147: An inhibitor of ACAT and the oxidative modification of LDL. Atherosclerosis 1994, 109(1-2): 89.
14. Bryzinski, B.S., Wrenn, S. Pharmacological effects of the ACATinhibitor CL 283,796. IBC 2nd Annu Conf Atheroscler. Adv Underst Treat (Feb 10-11, Philadelphia) 1994.
15. Yasuhara, M., Saito, K., Kubota, H., Ohmizu, H., Suzuki, T. Inhibitory effect of a new ureidophenol derivative T-2591 on LDL oxidation and ACAT activity. Biol Pharm Bull 1997, 20: 1056-60.
16. Kogushi, M., Tanaka, H., Kobayashi, H., Yamada, T., Ohtsuka, I., Kimura, T., Saito, I. Effect of E5324, a novel inhibitor of acyl-CoA:cholesterol acyltransferase, on cholesteryl ester synthesis and accumulation in macrophages. Jpn J Pharmacol 1995, 68: 191-9.
17. Roth, B.D., Blankley, C.J., Hoefle, M.L., Holmes, A., Roark, W.H., Trivedi, B.K., Essenburg, A.D., Kieft, K.A., Krause, B.R., Stanfield, R.L. Inhibitors of acyl-CoA:cholesterol acyltransferase. 1. Identification and structure-activity relationships of a novel series of fatty acid anilide hypocholesterolemic agents. J Med Chem 1992, 35: 1609-17.
18. Lee, H.T., Sliskovic, D.R., Picard, J.A. et al. Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents. Cl-1011: An acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J Med Chem 1996, 39: 5031-4.
19. Krause, B.R., Pape, M., Rea, T., Bousley, R., Stanfield, R., Kieft, K., Anderson, M.K., Lee, H., Homan, R. Cl-1011: A novel cholesterol-lowering compound in both chow-fed and cholesterol-fed rodent and nonrodent species. 12th Int Symp Drugs Affect Lipid Metab (Nov 7-10, Houston) 1995, 136.
20. Tanaka, A., Terasawa, T., Hagihara, H., Sakuma, Y., Ishibe, N., Sawada, M., Takasugi, H., Tanaka, H. Inhibitors of acyl-CoA:cholesterol O-acyltransferase. 2. Identification and structure-activity relationships of a novel series of N-alkyl-N-(heteroaryl-substituted benzyl)-N′-arylureas. J Med Chem 1998, 41: 2390-410.
21. Higley, C.A., Wilde, R.G., Maduskuie, T.P., Johnson, A.L., Pennev, P., Billheimer, J.T., Robinson, C.S., Gillies, P.J., Wexler, R.R. Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: Synthesis and structure-activity relationship studies of a new series of trisubstituted imidazoles. J Med Chem 1994, 37: 3511-22.
22. Junquéro, D., Puech, L., Béneteau, N., Barthes, V., Patoiseau, J.-F., Autin, J.-M., Donate, S., Colpaert, F.C., Delhon, A. F 12511: A potent inhibitor of cholesterol esterification in cultured cells. 11th Int Symp Atheroscler (Oct 5-9, Paris) 1997, Abst 385.
23. Kamiya, S., Shirahase, H., Yomishi, S., Kanda, M., Murase, K., Kurahashi, K. KY-455, a new bioavailable ACAT inhibitor with anti-peroxidative activity. Atherosclerosis 1997, 134(1-2): Abst 2.P.49.
24. Azuma, Y., Ikemoto, K., Obata, K., Mikami, H., Sajiki, N., Ohno, K., Yamada, T., Yamasaki, M., Nobuhara, Y. Effects of NTE-122, a new ACAT inhibitor, on cholesterol ester secretion in hepatic cells, and foam cell formation from macrophages. Jpn J Pharmacol 1997, 73(Suppl. 1): Abst P-565.
25. Kawasaki, T., Azuma, Y., Ikemoto, K., Mikami, H., Yamada, T., Nobuhara, Y. Pharmaco-biochemical properties of NTE-122, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor. Jpn J Pharmacol 1996, 71(Suppl. 1): Abst P-764.
26. Bello, A.A., Bright, C., Burton, B.J. et al. RP 64477: A potent inhibitor of acyl-coenzyme A. Cholesterol O-acyltransferase with low systemic bioavailability. Biochem Pharmacol 1996, 51: 413-21.
27. Ashton, M.J., Bridge, A.W., Bush, R.C., Dron, D.I., Harris, N.V., Jones, G.D., Lythgoe, D.J., Riddell, D., Smith, C. RP 70676: A potent systemically available inhibitor of acyl-CoA:cholesterol O-acyl transferase (ACAT). Bioorg Med Chem Lett 1992, 2: 375-80.
28. Asami, Y., Ohta, Y., Yamagishi, I., Murakami, S., Araki, H., Higuchi, S. Effects of a novel ACAT inhibitor HL-004 on cholesterol absorption in cholesterol-fed models. Jpn J Pharmacol 1996, 71(Suppl. 1): Abst P-362.
29. Murakami, S., Ohta, Y., Asami, Y., Yamagishi, I., Toda, Y., Araki, H., Otomo, S. Hypolipidemic effects of HL-004, a novel ACAT inhibitor, in hamsters fed normal chow. Atherosclerosis 1994, 109(1-2): Abst 204.
30. Matsuda, K., Ito, N., Iwaoka, K., Miyauchi, H., Iizumi, Y. Synthesis and hypolipidemic activity of tricyclic-arylmethyl substituted ureas: Potent ACAT inhibitors. 12th Int Symp Med Chem (Sept 13-17, Basel) 1992, Abst P-093.B.
31. Kashiwa, M., Masuyama, Y., Miyauchi, H. et al. Pharmacological properties of YM17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs. Jpn J Pharmacol 1997, 73: 41-50.